Volume 2.02 | Jan 21

Prostate Cell News 2.02, January 21, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Targeted Delivery of a Cisplatin Prodrug for Safer and More Effective Prostate Cancer Therapy In Vivo
Scientists demonstrate enhanced in vivo pharmacokinetics, biodistribution, tolerability, and efficacy of Pt-PLGA-b-PEG-Apt-NP (150±15 nm encapsulating ~5% wt/wt Pt(IV) prodrug) when compared to cisplatin administered in its conventional form in normal Sprague Dawley rats, Swiss Albino mice, and the prostate specific membrane antigen-expressing LNCaP subcutaneous xenograft mouse model of prostate cancer, respectively. [Proc Natl Acad Sci USA]



A Very Sad Loss – Stem Cell Pioneer Ernest A. McCulloch Passes Away
It is with great sadness that scientists honour the life and extraordinary contributions of Dr. Ernest “Bun” McCulloch who passed away on Wednesday, January 19th, 2011. Dr. McCulloch, along with his close friend and colleague, Dr. James Till, was a pioneer in the field of stem cell research. [Canadian Stem Cell Foundation Press Release]

Facebook Cell Therapy News is now on Facebook. Join us! 

Twitter Follow us on Twitter! @ProstateCell

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]


MicroRNA Prostate Cancer Stem Cells and Metastasis
A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. [Press release from MD Anderson Cancer Center discussing online prepublication in Nature Medicine]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


The microRNA miR-34a Inhibits Prostate Cancer Stem Cells and Metastasis by Directly Repressing CD44
Researchers show, through expression analysis, that miR-34a, a p53 target, was underexpressed in CD44+ prostate cancer cells purified from xenograft and primary tumors. [Nat Med]

Alpha- Versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
In this study, two novel (213)Bi-labeled peptides, DOTA-PEG(4)-bombesin (DOTA-PESIN) and DO3A-CH(2)CO-8-aminooctanoyl-Q-W-A-V-G-H-L-M-NH(2) (AMBA), were compared with (177)Lu (beta-emitter)-labeled DOTA-PESIN in a human androgen-independent prostate carcinoma xenograft model (PC-3 tumor). [Cancer Res]

NF-kB and c-Jun Induce the Expression of the Oncogenic miR-221 and miR-222 in Prostate Carcinoma and Glioblastoma Cells
Investigators report that the ectopic modulation of NF-kB modifies miR-221/222 expression in prostate carcinoma and glioblastoma cell lines, where they had previously shown their oncogenic activity. [Nucleic Acids Res]

Inhibition of Androgen Receptor Activity by Histone Deacetylase 4 Through Receptor SUMOylation
The transcriptional activity of the androgen receptor (AR) is regulated by both ligand binding and post-translational modifications, including acetylation and small ubiquitin-like modifier (SUMO)ylation. Histone deacetylases (HDACs) are known to catalyze the removal of acetyl groups from both histones and non-histone proteins. In this study, investigators report that HDAC4 binds to and inhibits the activity of the AR. [Oncogene]

Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer
Scientists show that apart from its primary direct cancer-killing activity, reovirus oncotherapy overrides tumor-associated immune evasion strategies and confers protective antiprostate cancer immunity. [Mol Ther]

Apoptotic Effect of Tolfenamic Acid in Androgen Receptor-Independent Prostate Cancer Cell and Xenograft Tumor through Specificity Protein 1
The study examined the role of tolfenamic acid in the death regulation of PC-3 and DU145 human androgen-independent prostate cancer cells. [Cancer Sci]

Hydroxyflutamide Enhances Cellular Sensitivity to 5-Fluorouracil by Suppressing Thymidylate Synthase Expression in Bicalutamide-Resistant Human Prostate Cancer Cells
Scientists investigated the antitumor effects of combination therapy with anti-androgens and 5-fluorouracil, and examined the underlying mechanism of the treatment. [Int J Oncol]

Hedgehog Overexpression Leads to the Formation of Prostate Cancer Stem Cells with Metastatic Property Irrespective of Androgen Receptor Expression in the Mouse Model
Investigators produced pCX-shh-IG mice that overexpress Hedgehog protein persistently in adult prostates, allowing for elucidation of the mechanism during prostate cancer initiation and progression. [J Biomed Sci]


The Effects of Body Mass Index on Changes in Prostate Specific Antigen Levels and Prostate Volume: Implications for Prostate Cancer Detection
The study’s objective is to investigate the association of body mass index (BMI) and BMI change with change in prostate specific antigen (PSA) level and to assess the possible roles of PSA hemodilution and prostate volume in explaining the obesity and PSA association. [Cancer Epidemiol Biomarkers Prev]

Evaluation of the Prognostic Significance of MSMB and CRISP3 in Prostate Cancer Using Automated Image Analysis
The purpose of the present study was to use automated image analysis, enabling quantitative determination of beta-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expressions in a large cohort and to validate the previous findings. [Mod Pathol]

D’Amico Risk Stratification Correlates With Degree of Suspicion of Prostate Cancer on Multiparametric Magnetic Resonance Imaging
Scientists determined whether there is a correlation between D’Amico risk stratification and the degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging based on targeted biopsies done with their electromagnetically tracked magnetic resonance imaging/ultrasound fusion platform. [J Urol]


Cancer Research UK and Cancer Research Technology Establish Team of Stem Cell Experts to Beat Cancer
Cancer Research UK and its commercial arm Cancer Research Technology, have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer. [Cancer Research UK Press Release]

MabCure Secures $10 Million Funding Commitment from an Institutional Investor Managed by Roswell Capital Partners
MabCure, Inc. announced the signing of a $10,000,000 Equity Funding Facility with Centurion Private Equity, LLC. MabCure intends to use the funding facility to fund clinical trials and ongoing research and development, and to support general corporate purposes. [MabCure, Inc. Press Release]

SIU Med School Receives Three Federal Grants
Two research scientists at Southern Illinois University (SIU) School of Medicine in Springfield have been awarded three grants by the Department of Defense U.S. Army Medical Research to study breast and prostate cancer. [Southern Illinois University Press Release]


SMC Accepts Degarelix (Firmagon®) for Advanced Hormone-Dependent Prostate Cancer
Following a resubmission, the Scottish Medicines Consortium (SMC) has accepted the gonadotropin-releasing hormone antagonist degarelix (Firmagon®) for use within National Health Service Scotland for the treatment of adult male patients with advanced hormone-dependent prostate cancer. [Scottish Medicines Consortium, Scotland]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us